A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRENONE (DRSP) AND A MONOPHASIC COC CONTAINING 20 MCG ETHINYLESTRADIOL (EE)/3 MG DRSP (YAZ®), ADMINISTERED ORALLY ONCE DAILY IN A 24/4 DAY REGIMEN FOR THREE CONSECUTIVE CYCLES

Trial Profile

A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRENONE (DRSP) AND A MONOPHASIC COC CONTAINING 20 MCG ETHINYLESTRADIOL (EE)/3 MG DRSP (YAZ®), ADMINISTERED ORALLY ONCE DAILY IN A 24/4 DAY REGIMEN FOR THREE CONSECUTIVE CYCLES

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Drospirenone/estetrol (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Estetra S.A.
  • Most Recent Events

    • 31 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top